Clinical utility of progesterone receptor modulators and their effect on the endometrium

Irving M Spitz
Current opinion in obstetrics & gynecology · 2009 · vol. 21(4) , pp. 318–324 · doi:10.1097/gco.0b013e32832e07e8 · PMID:19602929 · W2126753591
review OA: closed CC0 ⤵ 26 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-13 ⓘ

Progesterone receptor modulators like mifepristone are effective for uterine fibroids and endometriosis, but require careful monitoring for unique endometrial changes that do not indicate hyperplasia.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

PURPOSE OF REVIEW: In view of the spate of recent publications related to mifepristone and some second generation progesterone receptor modulators (PRMs), this appears to be an opportune time to view the clinical status of these compounds. RECENT FINDINGS: Randomized double-blind placebo-controlled trials have been conducted with mifepristone, CDB-4124 (Proellex), CDB-2914 (VA 2914, Ulipristal) and asoprisnil (J867). All these PRMs are effective in the treatment of uterine fibroids where they are associated with a reduction in pain, bleeding and improvement in quality of life and decrease in fibroid size. CDB-4124 is also efficacious in endometriosis. Long-term treatment with PRMs may be associated with endometrial thickening on ultrasound and there have been reports of endometrial hyperplasia. Several reassuring recent publications have done much to explain the mechanism underlying these endometrial changes. The most common histological finding is cystic glandular dilatation often associated with both admixed estrogen (mitotic) and progestin (secretory) epithelial effects. This histology has not been previously encountered in clinical practice and should not be confused with endometrial hyperplasia. The endometrial thickness is related to this cystic glandular dilatation. SUMMARY: At this stage of development, PRMs cannot be administered for longer than 3 or 4 months. Even over this time, there is improvement of symptoms associated with fibroids and endometriosis. Clinicians and pathologists need to be aware that the endometrial thickening and histological appearance do not represent endometrial hyperplasia.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometrium Endometrium Hormone Antagonists Receptors, Progesterone Drug Administration Schedule Endometriosis Endometriosis Endometriosis Endometrium Estrenes Estrenes Estrenes Female Hormone Antagonists Hormone Antagonists Humans Leiomyoma Leiomyoma Leiomyoma Mifepristone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (47)

Cited by (26)

Source provenance

europepmc
last seen: 2026-06-17T06:13:18.893374+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:13:59.677786+00:00
unpaywall
last seen: 2026-06-13T06:42:57.164913+00:00
License: CC0 · commercial use OK